Cite
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.
MLA
Machin, D., and K. W. Andersen. “Randomized Trial of Two versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer.” Journal of the National Cancer Institute, vol. 89, no. 9, May 1997, pp. 659–60. EBSCOhost, https://doi.org/10.1093/jnci/89.9.659.
APA
Machin, D., & Andersen, K. W. (1997). Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Journal of the National Cancer Institute, 89(9), 659–660. https://doi.org/10.1093/jnci/89.9.659
Chicago
Machin, D, and K W Andersen. 1997. “Randomized Trial of Two versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer.” Journal of the National Cancer Institute 89 (9): 659–60. doi:10.1093/jnci/89.9.659.